In this latest article from ASCO, we continue our strategic read on emerging data from Chicago. We’re shifting focus to a different niche – here’s what the lung cancer space is learning, what it still doesn’t know, and where things are likely headed.

Sometimes all is not as it seems

This example specifically explores the mutant selective KRAS field where the latest readouts are decoded in terms of the data, gaps to watch out for, and implications to consider going forward.

Just three years ago drugging KRAS was the hottest and most hyped area in oncology, yet it has struggled to live up to the unrealistic expectations.

Now, with second generation KRAS G12C and G12D agents emerging from ASCO, the picture becomes both clearer and also more complicated.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers